1/13/2012

The Juvenile Diabetes Research Foundation plans to offer up to $2.2 million to help advance clinical trials for KalVista's plasma kallikrein inhibitor and gather data for the treatment's potential in addressing diabetes-related macular edema.

Related Summaries